Dopamine D2 receptor gene polymorphisms in newborn infants of drug-using women

Oei, Ju Lee; Xu, Hong Xiu; Abdel-Latif, Mohamed E; Vunnam, Krishna; Al-Amry, Adil; Clews, Sarah; Falconer, Janet; Feller, John M; Lui, Kei

doi:10.1136/archdischild-2011-300235

Cited by 13 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of a significant relationship between maternal methadone dose and meconium concentrations of methadone and its metabolites and NAS severity (Gray et al, 2010; Kuschel et al, 2004) suggests that neonates differ in the rate of elimination of methadone from their systems. Metabolism of methadone by the placenta (Nanovskaya et al, 2004), fetus (Kuschel et al, 2004), and infant (Rosen et al, 1976) are likely to play a role in the variable expression of NAS among opioid-exposed infants, and may additionally be affected by other factors such as genetics (Oei et al, 2012), although the nature of these relationships have yet to be fully elucidated.…”

Section: Discussionmentioning

confidence: 99%

The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations

Jones

Jansson

O’Grady

et al. 2013

Neurotoxicology and Teratology

View full text Add to dashboard Cite

Compared to untreated opioid dependence, methadone maintenance treatment of opioid-dependent pregnant women has been found to be associated with better maternal and neonatal outcomes. Secondary analysis of data from 73 maternal and neonatal participants in the MOTHER study (H. E. Jones et al., New England Journal of Medicine, 2010) found no relationship between maternal methadone dose at delivery and any of 9 neonatal outcomes – peak neonatal abstinence syndrome (NAS) score, total amount of morphine needed to treat NAS, duration of neonatal hospital stay, duration of treatment for NAS, estimated gestational age at delivery, Apgar score at 5 minutes, and neonatal head circumference, length, and weight at birth. These results are consistent with a recent systematic review and meta-analysis (B. J. Cleary et al., Addiction, 2010) and extend findings to outcomes other than NAS. Methodological and design issues that might have adversely impacted the ability of researchers to establish the existence or non-existence of these relationships are considered.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations

Jones

Jansson

O’Grady

et al. 2013

Neurotoxicology and Teratology

View full text Add to dashboard Cite

show abstract

“…One area of ongoing research includes the assessment of genetic factors that could be contributing to the wide range of NOWS symptomatology in different infants. [40][41][42] As DNA can be evaluated using saliva samples, there may be clinical utility in determining specific maternal and infant genetic makeup in the future to non-invasively assess NOWS severity, although these approaches require further investigation and validation.…”

Section: Non-invasive Assessmentsmentioning

confidence: 99%

Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant

Schiff

Grossman

2019

Seminars in Fetal and Neonatal Medicine

View full text Add to dashboard Cite

Infants with in-utero opioid exposure are most commonly assessed using the Finnegan Neonatal Abstinence Scoring System (FNASS) or a modified version of that tool. Traditionally, the purpose of these tools has been to characterize the extent of withdrawal signs to guide the pharmacologic treatment for infants with neonatal opioid withdrawal syndrome (NOWS). In the past decade however, in response to some of the limitations of the FNASS tool, there has been an increasing emphasis on developing novel assessment tools not based on the FNASS in addition to the promotion of non-pharmacologic treatment options as the first line treatment for infants with opioid exposure. Additionally, several prediction tools that may be useful in determining which patients are at high or low risk for receiving pharmacologic therapy have been developed. In this review, we will evaluate the clinical utility of these novel tools and will consider new avenues for future research.

show abstract

“…This heritability has prompted case–control studies that have examined the association of several single-nucleotide polymorphisms (SNPs) in genes known to be involved in opioid metabolism and addiction with length of hospitalization, need for pharmacologic treatment, and total days of opioid treatment in neonates with NAS ( 12 ) (Table 1 ). Results suggest that SNPs in both mother and infant are associated with severity of NAS ( 2 , 15 – 17 ). For example, in studies of opioid-exposed newborn infants and their mothers ( 2 , 15 ), SNPs in maternal and infant genes that encode the μ-opioid receptor ( OPRM1 ), catechol- O -methyltransferase ( COMT ), and prepronociceptin ( PNOC ) were associated with differences in neonatal outcomes (length of hospitalization and reduced need for treatment with two medications).…”

Section: Associations Of Genomic Variants With Nas Risk and Severitymentioning

confidence: 99%

“… b Maternal allele . c Combined annotation-dependent depletion ( 17 ) . EA, European–American; Afr, African; N/A, not applicable (frame shift) .…”

Section: Associations Of Genomic Variants With Nas Risk and Severitymentioning

confidence: 99%

The Genomics of Neonatal Abstinence Syndrome

2017

View full text Add to dashboard Cite

Significant variability has been observed in the development and severity of neonatal abstinence syndrome (NAS) among neonates exposed to prenatal opioids. Since maternal opioid dose does not appear to correlate directly with neonatal outcome, maternal, placental, and fetal genomic variants may play important roles in NAS. Previous studies in small cohorts have demonstrated associations of variants in maternal and infant genes that encode the μ-opioid receptor (OPRM1), catechol-O-methyltransferase (COMT), and prepronociceptin (PNOC) with a shorter length of hospital stay and less need for treatment in neonates exposed to opioids in utero. Consistently falling genomic sequencing costs and computational approaches to predict variant function will permit unbiased discovery of genomic variants and gene pathways associated with differences in maternal and fetal opioid pharmacokinetics and pharmacodynamics and with placental opioid transport and metabolism. Discovery of pathogenic variants should permit better delineation of the risk of developing more severe forms of NAS. This review provides a summary of the current role of genomic factors in the development of NAS and suggests strategies for further genomic discovery.

show abstract

Dopamine D2 receptor gene polymorphisms in newborn infants of drug-using women

Abstract: DRD2 polymorphisms are detectable from DNA obtained from stored blood spots. The -ins allele is more common in control and unmedicated drug-exposed infants. Further study is recommended to explore postneonatal outcomes especially in relation to neuropsychiatric behaviours.

Cited by 13 publications

References 37 publications

The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations

The relationship between maternal methadone dose at delivery and neonatal outcome: Methodological and design considerations

Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant

The Genomics of Neonatal Abstinence Syndrome

Contact Info

Product

Resources

About